Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

247 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cisplatin resistance and oncogenes--a review.
Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Dempke W, et al. Among authors: voigt w. Anticancer Drugs. 2000 Apr;11(4):225-36. doi: 10.1097/00001813-200004000-00001. Anticancer Drugs. 2000. PMID: 10898536 Review.
The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors.
Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ. Grothey A, et al. Among authors: voigt w. J Cancer Res Clin Oncol. 1999;125(3-4):166-73. doi: 10.1007/s004320050259. J Cancer Res Clin Oncol. 1999. PMID: 10235470 Review.
Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W, Vanhoefer U, Yin MB, Minderman H, Schmoll HJ, Rustum YM. Voigt W, et al. Anticancer Res. 1997 Sep-Oct;17(5A):3707-11. Anticancer Res. 1997. PMID: 9413228
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ. Arnold D, et al. Among authors: voigt w. Br J Cancer. 2009 Oct 20;101(8):1241-7. doi: 10.1038/sj.bjc.6605327. Epub 2009 Sep 22. Br J Cancer. 2009. PMID: 19773753 Free PMC article. Clinical Trial.
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Voigt W, et al. J Cancer Res Clin Oncol. 2005 Sep;131(9):585-90. doi: 10.1007/s00432-005-0673-0. Epub 2005 Oct 20. J Cancer Res Clin Oncol. 2005. PMID: 16021466
Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin.
Dempke W, Voigt W, Grothey A, Schmoll HJ. Dempke W, et al. Among authors: voigt w. Anticancer Drugs. 1999 Jul;10(6):545-9. doi: 10.1097/00001813-199907000-00006. Anticancer Drugs. 1999. PMID: 10885902
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Bokemeyer C, Fels LM, Dunn T, Voigt W, Gaedeke J, Schmoll HJ, Stolte H, Lentzen H. Bokemeyer C, et al. Among authors: voigt w. Br J Cancer. 1996 Dec;74(12):2036-41. doi: 10.1038/bjc.1996.673. Br J Cancer. 1996. PMID: 8980410 Free PMC article.
Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ. Voigt W, et al. Clin Cancer Res. 2000 May;6(5):2087-93. Clin Cancer Res. 2000. PMID: 10815936
Monoterpenes as drug shuttles: cytotoxic (6-aminomethylnicotinate)dichloridoplatinum(II) complexes with potential to overcome cisplatin resistance.
Schobert R, Biersack B, Dietrich A, Grotemeier A, Müller T, Kalinowski B, Knauer S, Voigt W, Paschke R. Schobert R, et al. Among authors: voigt w. J Med Chem. 2007 Mar 22;50(6):1288-93. doi: 10.1021/jm061379o. Epub 2007 Mar 1. J Med Chem. 2007. PMID: 17328536
2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin.
Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A, Schmoll HJ, Kloft C, Voigt W. Dietrich A, et al. Among authors: voigt w. J Med Chem. 2008 Sep 11;51(17):5413-22. doi: 10.1021/jm800334z. Epub 2008 Aug 13. J Med Chem. 2008. PMID: 18698754
247 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback